Each 1ml of survanta contains 25mg of total phospholipids (beractant): Intratracheal suspension.
Ind: Treatment and prevention of neonatal respiratory distress syndrome (RDS).
S/E: Transient bradycardia has occurred.
Precautions: The specified dosing procedure for survanta should be followed carefully as errors could result in hyperinflation or obstruction of separate areas of the lungs. Close monitoring of arterial blood gases, the fraction of inspired oxygen, and ventilatory pressures is mandatory.
Dosage & admin: The recommended dose of survanta is 100mg phospholipid/kg body. weight administered intratracheally in a volume not exceeding 4ml/kg. It is recommended that survanta should be administered in two
half-doses (or four quarter-doses) through a neonatal suction valve, with the infant in different positions to ensure homogenous distribution. Treatment should be administered early in the course of RDS, i.e preferably in
babies less than 8 hours of age. For treatment and prophylaxis of RDS in high risk infants, up to four doses of survanta may be administered within 48 hours. The first dose is given at 15 minutes postpartum, with up to three
additional doses at intervals of at least six hours. Unopened, unused vials of survanta that have been warmed to room temperature, may be returned to the refrigerator within 8 hours of warming, and stored for future use. Survanta should not be warmed and re-refrigerated more than once. Used vials containing residual medicine should be discarded.
Note: For full prescribing information, please consult manufacturer's literature.
4ml vial: 20726.73 MRP